Why the study?
Does elevated preoperative platelet count or platelet-lymphocyte ratio predict worse survival in patients with colorectal cancer and hepatic metastasis?
Does elevated preoperative platelet count or platelet-lymphocyte ratio predict worse survival in patients with colorectal cancer and hepatic metastasis?
Answers are grounded in this paper and cite their sources.
Elevated preoperative platelet count, but not platelet-lymphocyte ratio, serves as an independent prognostic marker for worse survival in patients with colorectal cancer and its hepatic metastases.
The aim of the present study was to analyse the preoperative platelet count and the platelet-lymphocyte ratio (PLR) in patients with colorectal cancer (CRC) of different stages and with hepatic metastasis of CRC (mCRC) and to compare these factors as potential prognostic markers. Clinicopathological data of 10 years were collected retrospectively from 336 patients with CRC and 118 patients with mCRC. Both in the CRC and the mCRC group overall survival (OS) was significantly worse in patients who had elevated platelet count (hazard ratio [HR] = 2.2, p < 0.001 and HR = 2.9, p = 0.018, respectively). Multivariate analysis indicated that elevated platelet count was an independent prognostic factor of CRC (HR = 1.7, p = 0.035) and mCRC (HR = 3.1, p = 0.017). Disease-free survival (DFS) was significantly worse in patients with elevated platelet count in the CRC group (HR = 2.0, p = 0.011). In the multivariate analysis the PLR was not a prognostic factor in either of the two cohorts (HR = 0.92, p < 0.001 and HR = 0.89, p = 0.789, respectively). The platelet count is a valuable prognostic marker for the survival in patients both with CRC and mCRC while the PLR is not prognostic in either group.
No takes yet. Share an insight, caveat, or question.
Krzystanek et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: